FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923132839> ?p ?o ?g. }

• W2923132839 endingPage "203" @default.
• W2923132839 startingPage "196" @default.
• W2923132839 abstract "Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease.To evaluate the safety/tolerability, immunogenicity, pharmacokinetics/pharmacodynamics, and efficacy of M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe plaque psoriasis.This multicenter, double-blind, placebo-controlled dose escalation phase 1 study randomized 44 patients 4:1 to treatment with subcutaneous M1095 (30, 60, 120, or 240 mg) or placebo biweekly for 6 weeks, in 4 ascending dose cohorts.The most frequent treatment-emergent adverse events with M1095 were pruritus (n = 4) and headache (n = 3); 2 patients withdrew owing to adverse events (injection site reaction and elevated liver enzyme levels). The terminal half-life of M1095 was 11 to 12 days. The area under the curve/maximum concentration was dose proportional. Of 10 M1095-treated patients positive for antidrug antibodies, 5 showed treatment-emergent antidrug antibody responses. There was no effect on M1095 exposure. Marked decreases in psoriasis inflammatory markers were observed with M1095. By day 85, 100% and 56% of patients receiving M1095, 240 mg, achieved psoriasis area and severity index 90 and 100, respectively. Improvements in static Physician's Global Assessment and affected body surface area were also seen.Interpretation of efficacy data is limited by the small sample size.Multiple subcutaneous doses of M1095 showed a favorable safety profile with dose-dependent improvements in psoriasis." @default.
• W2923132839 created "2019-04-01" @default.
• W2923132839 creator A5004108054 @default.
• W2923132839 creator A5020251765 @default.
• W2923132839 creator A5040720239 @default.
• W2923132839 creator A5047502465 @default.
• W2923132839 creator A5057168110 @default.
• W2923132839 creator A5080337749 @default.
• W2923132839 date "2019-07-01" @default.
• W2923132839 modified "2023-10-14" @default.
• W2923132839 title "A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti–interleukin 17A/F nanobody, in moderate-to-severe psoriasis" @default.
• W2923132839 cites W1849511347 @default.
• W2923132839 cites W1982078500 @default.
• W2923132839 cites W1982598880 @default.
• W2923132839 cites W1991647625 @default.
• W2923132839 cites W1992608692 @default.
• W2923132839 cites W2024173356 @default.
• W2923132839 cites W2041564493 @default.
• W2923132839 cites W2065136791 @default.
• W2923132839 cites W2112128505 @default.
• W2923132839 cites W2127834887 @default.
• W2923132839 cites W2322390243 @default.
• W2923132839 cites W2518865922 @default.
• W2923132839 cites W2752721387 @default.
• W2923132839 cites W2779290422 @default.
• W2923132839 cites W2794845062 @default.
• W2923132839 doi "https://doi.org/10.1016/j.jaad.2019.03.056" @default.
• W2923132839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30926369" @default.
• W2923132839 hasPublicationYear "2019" @default.
• W2923132839 type Work @default.
• W2923132839 sameAs 2923132839 @default.
• W2923132839 citedByCount "43" @default.
• W2923132839 countsByYear W29231328392019 @default.
• W2923132839 countsByYear W29231328392020 @default.
• W2923132839 countsByYear W29231328392021 @default.
• W2923132839 countsByYear W29231328392022 @default.
• W2923132839 countsByYear W29231328392023 @default.
• W2923132839 crossrefType "journal-article" @default.
• W2923132839 hasAuthorship W2923132839A5004108054 @default.
• W2923132839 hasAuthorship W2923132839A5020251765 @default.
• W2923132839 hasAuthorship W2923132839A5040720239 @default.
• W2923132839 hasAuthorship W2923132839A5047502465 @default.
• W2923132839 hasAuthorship W2923132839A5057168110 @default.
• W2923132839 hasAuthorship W2923132839A5080337749 @default.
• W2923132839 hasBestOaLocation W29231328391 @default.
• W2923132839 hasConcept C111113717 @default.
• W2923132839 hasConcept C112705442 @default.
• W2923132839 hasConcept C126322002 @default.
• W2923132839 hasConcept C142724271 @default.
• W2923132839 hasConcept C168563851 @default.
• W2923132839 hasConcept C197934379 @default.
• W2923132839 hasConcept C203014093 @default.
• W2923132839 hasConcept C204243189 @default.
• W2923132839 hasConcept C204787440 @default.
• W2923132839 hasConcept C27081682 @default.
• W2923132839 hasConcept C2776390293 @default.
• W2923132839 hasConcept C2777011040 @default.
• W2923132839 hasConcept C2777501473 @default.
• W2923132839 hasConcept C2778375690 @default.
• W2923132839 hasConcept C2778690821 @default.
• W2923132839 hasConcept C2780564577 @default.
• W2923132839 hasConcept C71924100 @default.
• W2923132839 hasConcept C74172505 @default.
• W2923132839 hasConcept C90924648 @default.
• W2923132839 hasConceptScore W2923132839C111113717 @default.
• W2923132839 hasConceptScore W2923132839C112705442 @default.
• W2923132839 hasConceptScore W2923132839C126322002 @default.
• W2923132839 hasConceptScore W2923132839C142724271 @default.
• W2923132839 hasConceptScore W2923132839C168563851 @default.
• W2923132839 hasConceptScore W2923132839C197934379 @default.
• W2923132839 hasConceptScore W2923132839C203014093 @default.
• W2923132839 hasConceptScore W2923132839C204243189 @default.
• W2923132839 hasConceptScore W2923132839C204787440 @default.
• W2923132839 hasConceptScore W2923132839C27081682 @default.
• W2923132839 hasConceptScore W2923132839C2776390293 @default.
• W2923132839 hasConceptScore W2923132839C2777011040 @default.
• W2923132839 hasConceptScore W2923132839C2777501473 @default.
• W2923132839 hasConceptScore W2923132839C2778375690 @default.
• W2923132839 hasConceptScore W2923132839C2778690821 @default.
• W2923132839 hasConceptScore W2923132839C2780564577 @default.
• W2923132839 hasConceptScore W2923132839C71924100 @default.
• W2923132839 hasConceptScore W2923132839C74172505 @default.
• W2923132839 hasConceptScore W2923132839C90924648 @default.
• W2923132839 hasFunder F4320311647 @default.
• W2923132839 hasIssue "1" @default.
• W2923132839 hasLocation W29231328391 @default.
• W2923132839 hasLocation W29231328392 @default.
• W2923132839 hasLocation W29231328393 @default.
• W2923132839 hasOpenAccess W2923132839 @default.
• W2923132839 hasPrimaryLocation W29231328391 @default.
• W2923132839 hasRelatedWork W1485326008 @default.
• W2923132839 hasRelatedWork W1975896731 @default.
• W2923132839 hasRelatedWork W1989170203 @default.
• W2923132839 hasRelatedWork W1990582125 @default.
• W2923132839 hasRelatedWork W2017151702 @default.
• W2923132839 hasRelatedWork W2059983379 @default.
• W2923132839 hasRelatedWork W2751316297 @default.
• W2923132839 hasRelatedWork W3176363967 @default.

• next